



September 14, 2020

Company name: SanBio Co., Ltd.
 Representative: Keita Mori, Representative Director
 and President
 (TSE Mothers Code: 4592)
 Contact: Yoshihiro Kakutani, Corporate Officer
 of Management Administration
 (TEL. +81-3-6264-3481)

Notice regarding change in director and corporate officer

SanBio Co., Ltd. (hereafter “SanBio” or “the Company”) hereby announces that at a Board of Directors meeting held today, it has resolved to make the following change to its director and corporate officer, effective September 15, 2020.

1. Details of change

For the development of the SanBio Group (SanBio and its subsidiary SanBio, Inc.) as a whole, the Company decided to appoint Akihiro Tsujimura to the position of Executive Vice President, Corporate Officer, and Chief Operating Officer (COO). Details of change in the position of Mr. Tsujimura are as follows.

<SanBio Co., Ltd.>

	Current position	New position
Akihiro Tsujimura	Corporate Officer, Senior Managing Director	Executive Vice president, Corporate Officer, and COO

< SanBio, Inc. >

	Current position	New position
Akihiro Tsujimura	CEO	CEO (no change)

2. Career summary

Name (date of birth)	Career summary
Akihiro Tsujimura (December 26, 1967)	1992 Joined Nichimen Corp. (current Sojitsu Corp.)
	2001 President & CEO, Biaxis Packaging Sales Inc., an overseas joint venture of Nichimen Corp.
	2004 Joined Santen Pharmaceutical Co., Ltd.
	2012 Corporate Officer, Santen Pharmaceutical Co., Ltd. President & CEO, Santen Inc.
	2015 Senior Executive Officer and Head of Asia Business, Santen Pharmaceutical Co., Ltd.
	2016 Executive Corporate Officer, Head of Corporate Development Division, and Head of Asia and North America Businesses, Santen Pharmaceutical Co., Ltd.

		President and CEO, Santen Inc.
	2017	Director, Santen Pharmaceutical Co., Ltd.
	2018	Joined SanBio Co., Ltd.
		Corporate officer, Senior Managing Director, SanBio Co., Ltd.
		CEO, SanBio, Inc.

Akihiro Tsujimura appointed Executive Vice President and COO

The SanBio Group (SanBio Co., Ltd. and its subsidiary SanBio, Inc.) hereby announces that it has resolved to appoint Akihiro Tsujimura—current Senior Managing Director of SanBio Co., Ltd. and CEO of SanBio, Inc.—to the position of Executive Vice President and Chief Operating Officer (COO), effective September 15, 2020 (September 14, 2020, US time) for the development of the Group as a whole.

Mr. Tsujimura accumulated diverse experience in corporate management while working at Nichimen Corp. (current Sojitsu Corp.), through his involvement in various operations ranging from the establishment and management of overseas businesses to corporate turnarounds in Japan. At Santen Pharmaceutical Co., Ltd., he gained a wealth of experience in pharmaceutical business operations, including business development, M&A, and overseas expansion. The SanBio Group expects Mr. Tsujimura to draw on his experience and track record in corporate management to make further contributions to the Group's global expansion. He will maintain his position of CEO at SanBio, Inc., the Company's U.S. subsidiary.

Currently, the SanBio Group is working toward filing for manufacture and marketing approval of SB623 as a regenerative medicine product for the treatment of chronic motor deficit from traumatic brain injury (TBI) in Japan by the end of the fiscal year ending January 2021 (February 2020–January 2021). As the new Vice President and COO of the Company, Mr. Tsujimura will oversee the entire operation of the Group, including making necessary preparations to launch SB623 as a therapeutic drug for the treatment of chronic effects resulting from TBI in Japan and in other countries thereafter (i.e., global development of the product), as well as preparations to resume clinical trials in the ischemic stroke program. Under his leadership, we will aim to maximize the value of SB623 and continue considering various development options, including in-house development and entering partnerships.

Mr. Tsujimura commented as below in regard to his new position:

“Ever since I joined the Company in October 2018, together with top management led by President Mori, as well as our members in Japan and the U.S., I worked to maximize the value of SB623 and also of SanBio. With the mission to deliver SB623 to patients as soon as possible, I take my appointment to the position of Vice President and COO seriously, and I will do my utmost to take SanBio to the next phase of growth.”

Representative Director and President Mori commented as follows:

“Since our founding in 2001, we have worked to develop new drugs in the novel field of regenerative cell medicine to contribute to improving the lives of patients facing difficulties, as well as of their family members. Amid numerous challenges we encountered as we navigated through the completely new field

of drug development, Mr. Tsujimura, as CEO of the Company's U.S. subsidiary SanBio, Inc. and as a member of management of the SanBio Group aiming to become a global leader, has demonstrated outstanding leadership and established strong presence both in and outside the Company. As SanBio transitions to a new phase, we expect him to make greater contributions to its development from his new post."

About SanBio Co., Ltd. and SanBio, Inc.

SanBio Group is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. The Company's propriety regenerative cell medicine product, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and ischemic stroke. The Company is headquartered in Tokyo, Japan and Mountain View, California, and additional information about SanBio Group is available at <https://sanbio.com>.

For more information, contact:

SanBio Co., Ltd.

Management Administration

info@sanbio.jp